| 摘要 |
<p>The use of ribavirin and interferon alpha for the manufacture of pharmaceutical compositions for treating a patient having chronic hepatitis C infection, e.g., a patient having HCV genotype 1, 2 or 3, to eradicate detectable HCV-RNA by a method comprising administering an effective amount of ribavirin in association with an effective amount of pegylated interferon alpha, characterised in that treating patients having chronic hepatitis C infections is effected in two treatment time periods: (a) a first treatment time period of at least 20 to 30 wherein a therapeutically effective amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g., pegylated interferon-alfa-2b sufficient to at least substantially lower, and preferably to eradicate, detectable HCV-RNA, are administered; and (b) a second treatment time period of at least 20 to 30 weeks wherein a therapeutically effective amount of ribavirin and a therapeutically effective amount of pegylated interferon-alfa are administered sufficient to maintian no detectable HCV-RNA for at least 20-30 weeks are administered after the end of the first treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period is disclosed.</p> |
